The association between Calcitonin Gene-Related Peptide (CGRP), substance P and headache in pituitary tumours

Pituitary

Volumn 7, Issue 2, 2004, Pages 67-71

  Levy, M J ^a,b   Classey, J D ^a   Maneesri, S ^a   Meeran, K ^b   Powell, M ^c   Goadsby, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Cluster headache; Migraine; Neuropeptide; Pituitary tumour associated headache

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CORTICOTROPIN; NEUROPEPTIDE; SUBSTANCE P;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLUSTER HEADACHE; CONTROLLED STUDY; CUSHING DISEASE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN DETERMINATION; PROTEIN FUNCTION;

ACROMEGALY; CALCITONIN GENE-RELATED PEPTIDE; HEADACHE; HUMANS; IMMUNOHISTOCHEMISTRY; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PREVALENCE; PROLACTINOMA; SUBSTANCE P;

EID: 14944376592     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-5347-z     Document Type: Article

References (50)

1. Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K. Headache associated with pituitary adenomas. Headache 1998;38:782-786.
2. Hennessy JV, Jackson IM. Clinical features and differential diagnosis of pitutiary tumours with emphasis on acromegaly. Baillieres Clinical Endocrinology and Metabolism 1995;9:271-234.
3. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:23-240.
4. Nabarro JD. Acromegaly. Clinical Endocrinology 1987;26: 481-512.
5. J Couch 1986 Toxic and metabolic headache. Handbook of Clinical Neurology Elsevier Amsterdam 417-430
6. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: Relevance to headache. Cephalalgia 1995;15:272-278.
7. Levy MJ, Jager HR, Matharu MS, Goadsby PJ. Pituitary tumours and headache: Does size matter? Cephalalgia 2002;22:592.
8. Pascual J. Headache relief after sumatriptan in a patient with pituitary macroadenoma. Headache 2000;40:399-400.
9. Williams G, Ball J, Bloom S, Joplin GF. Improvement in headache associated with prolactinoma during treatment with somatostatin analogue: An "N of 1" study. New England Journal of Medicine 1986;315:1166-1167.
10. Millan Guerrero RO, Isais Cardenas MA. Headache associated with pituitary adenomas. Headache 1999;39:522-523.
11. Massiou H, Launay JM, Levy C, El Amran M, Emperauger B, Bousser M-G. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology 2002;58:1698-1699.
12. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998;83: 3034-3040.
13. Pascual J, Freijares J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Pain 1991;47:341-344.
14. Williams G, Ball JA, Lawson RA, Joplin GF, Bloom SR, Maskill MR. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. British Medical Journal 1987;295:247-248.
15. Levy MJ, Barakat M, Bejon P, Goadsby PJ, Meeran K. Acromegaly: A unique human headache model? Headache 2003;43:794-797.
16. Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neuroscience and Biobehavioural Reviews 1997;21:649-678.
17. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Trequattrini A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-390.
18. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology 1990;28:183-187.
19. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995;60:119-123.
20. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994;117:427-434.
21. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. Journal of Comparative Neurology 1991;309:515-534.
22. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neuroscience Letters 1985;62:131-136.
23. Gibson SJ, Polak JM, Bloom SR, Sabate IM, Mulderry PM, Ghatei MA, et al. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. Journal of Neuroscience 1984;4:101-111.
24. Hokfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. Journal of Internal Medicine 2001;249:27-40.
25. Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 2000;34:256-271.
26. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Annals of Neurology 1988;23:193-196.
27. Steel JH, Gon G, Giaid A, O'Halloran DJ, Emson MA, Van Noorden S, et al. Localization of calcitonin gene-related peptide in the rat and human pituitary gland using immunocytochemistry and in situ hybridization. CGRP expression during ontogeny and after endocrine manipulations. Annals of the New York Academy of Sciences 1992;657:135-154.
28. Jessop DS, Chowdrey HS, Larsen PJ, Lightman SL. Substance P: Multifunctional peptide in the hypothalamo-pituitary system? Journal of Endocrinology 1992;132:331-337.
29. Wimalawansa S. Expression of CGRP in pituitary and pituitary adenoma. 76th Annual Meeting of the Endocrine Society. Anaheim, CA, 1994.
30. Roth KA, Krause JE. Substance-P is present in a subset of thyrotrophs in the human pituitary. Journal of Clinical Endocrinology and Metabolism 1990;71:1089-1095.
31. Levy MJ, Classey JD, Maneesri S, Powell M, Meeran K, Goadsby PJ. Differential expression of calcitonin gene-related peptide (CGRP) and substance P in pituitary adenomas: In search of a nociceptive peptide. Cephalalgia 2003;23:687.
32. Headache Classification Committee of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.
33. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (2nd ed.). Cephalalgia 2004;24(Suppl 1): 1-160.
34. Burry RW. Specificity controls for immunocytochemical methods. Journal of Histochemistry and Cytochemistry 2000;48:163-165.
35. Arita J, Kojima Y, Yamamoto I, Mazawa S, Kimura F. Somatotropes and thyrotropes in the rat anterior pituitary gland cosecrete substance P: Analysis by the sandwich cell immunoblot assay. Neuroendocrinology 1994;60:567-574.
36. Edvinsson L, Goadsby PJ. Neuropeptides in headache. European Journal of Neurology 1998;5:329-341.
37. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. New England Journal of Medicine 2002;346:257-270.
38. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003;23:519-527. 10.1046/j.1468-2982.2003.00568.x
39. Levy MJ, Matharu MS, Powell MP, Meeran K, Goadsby PJ. Phenoytpic characterisation of the headache associated with pituitary tumours. Cephalalgia 2003;23:621.
40. Afra J, Czirjak S. Headache characteristics in patients with pituitary tumours. Cephalagia 2003;23:671.
41. Greve E, Mai J. Cluster headache-like headaches: A symptomatic feature? A report of three patients with intracranial pathologic findings. Cephalalgia 1988;8:79-82.
42. Milos P, Havelius U, Hindfelt B. Clusterlike headache in a patient with a pituitary adenoma. With a review of the literature. Headache 1996;36:184-188.
43. Porta-Etessam J, Ramos-Carrasco A, Berbel-Garcia A, Martinez-Salio A, Benito-Leon J. Clusterlike headache as first manifestation of a prolactinoma. Headache 2001;41:723-725.
44. Levy MJ, Matharu MS, Goadsby PJ. Prolactinomas, dopamine agonist and headache: Two case reports. European Journal of Neurology 2003;10:169-174.
45. Matharu MS, Levy MJ, Merry RT, Goadsby PJ. SUNCT syndrome secondary to prolactinoma. Journal of Neurology, Neurosurgery and Psychiatry 2003;74:1590-1592.
46. Grouzmann E, Deruaz JP, Gomez F, Waeber C. Immunolocalization of neuropeptide Y in human pituitary tumours. Regulatory Peptides 1998;75:89-92.
47. Jansen I, Goadsby PJ, Uddman R, Edvinsson L. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation. Journal of the Autonomic Nervous System 1994;49:S97-S103.
48. Hsu DW, Riskind PN, Hedley-Whyte ET. Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study. American Journal of Pathology 1989;135:329-338.
49. Suwanwela N, Phanthumchinda K, Kaoropthum S. Headache in brain tumor: A cross-sectional study. Headache 1994;34:435-438.
50. Ferrari MD, Haan J, van Seters AP. Bromocriptine-induced trigeminal neuralgia attacks in a patient with pituitary tumor. Neurology 1988;38:1482-1484.